FDA Approves Donanemab for Early-Stage Alzheimer's Treatment
On July 2, 2024, the FDA officially approved Eli Lilly's new Alzheimer's medication, donanemab. Sold under the brand name Kisunla, this drug marks a major step forward for patients in the early…